ZOM dumping againRejected.
There next earnings report is August 7th.
It could not get above the 0.16 mark.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0571USD
−34.53 MUSD
25.19 MUSD
962.51 M
About Zomedica Corp.
Sector
CEO
Larry C. Heaton
Headquarters
Ann Arbor
Website
Founded
2013
FIGI
BBG00DGZC7Y0
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.
ZomedicaZom has to make a base here at .16 or else the stock will go to all time lows.
The stocks Low before pumping was .07 cents.
The company seems to be doing well at Trade shows and has $140 million in cash reserves, but this is not reflected.
Earnings have been increasing.
$ZOM Potent investment opportunityObserving the trading chart for this particular equity, it's evident that the security has been encapsulated in a range-bound, or "rectangular," pattern since 2018, with the central pivot point firmly established in the $0.20 vicinity. This technical analysis, combined with strategic stock purchases
ZOM LongPrice has been consolidating in the .24-.25 range since May which is also in very close proximity to the POC (12 Month) suggesting this could be a low risk entry point as the most shares traded in 12 months has been at .2424 cents.
The Force Index is curling up, the D+ crossed the D- on the ADX an
ZOM upside potentialZomedica Corp. (ZOM) was one of the top meme stocks of 2021.
i think a bounce to 0.51 and 0.90 resistance levels is still possible.
Looking forward to read your opinion about it.
Zomedica(an interesting play)As a risky play it also offers huge potential, fundamentals are showing progress towards the positive side and the latest acquisition of PulseVet will allow the company to become an strong player in the market. (Golden Cross, MACD, Divergence)
Zom slowly waking upNot a Financial advisor.
Zom appears to have found a potential bottom - awaiting this week to close (market rebounding - should look to be green)
This is a satisfying entry level for me personally to go long. Lower time frames a bit more bullish than the weekly. Should translate to the higher tim
Zomedica OutlookBullish divergence on the daily as of time of posting, however, macro bearish!
Target is support, and RSI needs to get oversold on the Weekly.
Once support is tested, ZOM can run again, or it can just reverse-split LOL.
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ZOM is 0.1202 USD — it has decreased by −0.50% in the past 24 hours. Watch Zomedica Corp. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Zomedica Corp. stocks are traded under the ticker ZOM.
ZOM stock has fallen by −1.07% compared to the previous week, the month change is a −11.03% fall, over the last year Zomedica Corp. has showed a −28.45% decrease.
ZOM stock is 1.93% volatile and has beta coefficient of 1.50. Track Zomedica Corp. stock price on the chart and check out the list of the most volatile stocks — is Zomedica Corp. there?
Today Zomedica Corp. has the market capitalization of 118.38 M, it has increased by 0.92% over the last week.
Yes, you can track Zomedica Corp. financials in yearly and quarterly reports right on TradingView.
Zomedica Corp. is going to release the next earnings report on Nov 7, 2024. Keep track of upcoming events with our Earnings Calendar.
Zomedica Corp. revenue for the last quarter amounts to 6.10 M USD, despite the estimated figure of 8.36 M USD. In the next quarter, revenue is expected to reach 8.70 M USD.
ZOM net income for the last quarter is −23.93 M USD, while the quarter before that showed −9.16 M USD of net income which accounts for −161.26% change. Track more Zomedica Corp. financial stats to get the full picture.
No, ZOM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 1, 2024, the company has 144.00 employees. See our rating of the largest employees — is Zomedica Corp. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Zomedica Corp. EBITDA is −29.39 M USD, and current EBITDA margin is −100.43%. See more stats in Zomedica Corp. financial statements.
Like other stocks, ZOM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Zomedica Corp. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Zomedica Corp. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Zomedica Corp. stock shows the strong sell signal. See more of Zomedica Corp. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.